Zogenix to Present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology

Press Release

« Back

Zogenix to Present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology

EMERYVILLE, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executive Vice President, Chief Financial Officer, Treasurer and Secretary, will present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology, being held October 2-3, 2018, in New York, NY.

Zogenix Presentation Details
Date:   Tuesday, October 2, 2018
Time:   10:30 AM Eastern Time / 7:30 AM Pacific Time
Location:   New York, NY - Lotte New York Palace Hotel
     

The presentation will be webcast live and archived for 30 days on Zogenix's Investor Relations website at https://zogenixinc.gcs-web.com.

About Zogenix
Zogenix (Nasdaq: ZGNX) is focused on developing therapies for patients with rare central nervous system (CNS) conditions that have limited or no treatment options but face a critical need. For more information, visit www.zogenix.com.

CONTACT:
Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | Andrew@lifesciadvisors.com 

Media: David Polk
Senior Media Relations Strategist, Syneos Health
310-309-1029 | david.polk@syneoshealth.com

Zogenix logo.jpg

Source: Zogenix, Inc.